

**BASIC
RESEARCH**

THE PROJECT FINANCED BY
THE POLISH NATIONAL AGENCY
FOR ACADEMIC EXCHANGE UNDER
THE WELCOME TO POLAND
PROGRAMME (2020)



POLISH NATIONAL AGENCY
FOR ACADEMIC EXCHANGE



Maria Skłodowska-Curie

**National Research
Institute of Oncology**




**GENETIC AND
TRANSLATIONAL
RESEARCH**

PATIENT

HOSPITAL

**CLINICAL
RESEARCH**

**EARLY PHASE
TRIALS
DEPARTMENT**



„New therapy development process starts on a laboratory bench. It is there, where we learn about carcinogenesis as well as immune system cancer prevention mechanisms. Our research is conducted in numerous areas.

As we must face new challenges, such as pandemic, we are currently developing Covid-19 treatment drug, working on CAR-T innovative technology as well as T-cell exhaustion by cancer cells.”

Elżbieta Sarnowska
MD, PhD

Due to translational research, which is one of the stages of targeted therapy, we are able to verify whether basic analysis outcomes translate into clinical research. Only then can pharmaceutical companies start producing specific drugs. At present, genetic research is the key stage of patient selection for targeted therapy, as well as tumor identification and classification.”

Andrzej Tysarowski
MD, PhD

Our mission starts in a laboratory, but it ends at the most important place - bedside. We always aim at finding and offering the best treatment program dedicated to a given patient.”

NID-PIB Director
Jan Walewski
MD

Those oncology patients who do not react to standard treatment, have the opportunity to take part in clinical research conducted at the Early Phase Trial department. We are conducting research on immunomodulatory drugs as well as molecularly targeted drugs.”

Iwona Rulawska
MD, PhD

Therefore, in order to fully assess new drug efficacy and effectiveness, large scale clinical research is required. The National Oncology Institute in Warsaw conducts approximately 500 clinical trials per year.”

Piotr Rutkowski
MD, PhD

Due to wide access to knowledge, we are able to select the optimal and best therapy for our patients. „We always aim at finding and offering the best treatment program dedicated to a given patient.”

Paweł Mieczno
MD, PhD

The selection of individual treatment methods for our patients is based on the results of complex molecular and genetic research; Agnieszka Jagieło-Grzesińska MD

„Due to a large number of patients treated at the Institute, we are able to conduct clinical research on new therapy methods. Human organism is extremely complex.